879487-10-2 Usage
Description
1H-Pyrazole, 1-(1-Methylethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, also known as 1-Isopropyl-1H-pyrazole-4-boronic acid pinacol ester, is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique structure, which includes a pyrazole ring and a boronic acid pinacol ester group, making it a versatile building block in organic synthesis.
Uses
Used in Pharmaceutical Industry:
1H-Pyrazole, 1-(1-Methylethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)is used as a reactant for the synthesis of Imidazo[1,2-a]pyrazine based phosphodiesterase 10A inhibitors. These inhibitors are important in the development of drugs targeting neurological disorders, such as schizophrenia and depression, due to their ability to modulate the activity of phosphodiesterase 10A, an enzyme implicated in these conditions.
Additionally, 1H-Pyrazole, 1-(1-Methylethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)is used as a reactant for the synthesis of Pyrido[3,4-d]pyrimidin-4-(3H)-one based KDM4 and KDM5 (histone lysine demethylase families) inhibitors. These inhibitors play a crucial role in the regulation of gene expression and have potential applications in the treatment of various diseases, including cancer, by targeting the epigenetic modifications of histone proteins.
Check Digit Verification of cas no
The CAS Registry Mumber 879487-10-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,9,4,8 and 7 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 879487-10:
(8*8)+(7*7)+(6*9)+(5*4)+(4*8)+(3*7)+(2*1)+(1*0)=242
242 % 10 = 2
So 879487-10-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H21BN2O2/c1-9(2)15-8-10(7-14-15)13-16-11(3,4)12(5,6)17-13/h7-9H,1-6H3
879487-10-2Relevant articles and documents
PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
-
Paragraph 0533; 0535-0536, (2022/02/28)
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).
AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF
-
Page/Page column 94; 110-111, (2021/02/26)
Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 0132, (2020/10/21)
Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
